Diagonal Therapeutics’ innovative clustering antibodies for vascular diseases

Episode 194

0:00-31:10

Today we’re joined by Patrick Andre, Chief Scientific Officer at Diagonal Therapeutics. A trained vascular biologist, Patrick’s career spans groundbreaking work at Pfizer, Acceleron, Pliant Therapeutics, and earlier companies, where he focused on TGF-β superfamily signaling and receptor pathways that keep blood vessels healthy. Now at Diagonal, he’s leading a bold mission: developing clustering antibodies that correct the root cause of serious genetic vasculopathies, rather than just managing symptoms. In this episode, Patrick walks us through his personal journey into science, the company’s DIAGONAL platform, and their lead program DIAG723, which recently received Orphan Drug Designation for the rare disease HHT, and is advancing toward the clinic. We also discuss Diagonal’s oversubscribed $125 million Series B financing that closed in January 2026, and what clustering antibodies could mean for patients with HHT, pulmonary arterial hypertension, and beyond. 01:33 Meet Patrick Andre 08:01 Diagonal’s mission 11:39 What are clustering antibodies 16:05 Receptor clustering benefits for HHT and PAH 20:24 Preclinical data on preventing and reversing HHT pathology 22:39 The impact of the $125 Million Series B financing round Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Publisher

Beyond Biotech - the podcast from Labiotech

Published

April 24, 2026

Duration

31 min

Format

Podcast

Category

Issues · Tech News

Source

RSS feed

Host

Labiotech

BB

Beyond Biotech - the podcast from Labiotech

@beyondbiotechthepodcastfroml

#diagonaltherapeuticsinnovative #vasculardiseases

The Nile